The first Lp(a) drug trial failed. The case for the test never depended on the drug.

On September 4, 2026, Novartis said pelacarsen lowered lipoprotein(a) but did not reduce heart attacks, strokes or cardiovascular death in 8,323 patients. The full results, published in NEJM on November 7, confirmed it, including in people with the highest levels. If you have an Lp(a) result on file, or have been meaning to order one, here is what changed and what did not.

The gist
Lp(a)HORIZON enrolled 8,323 people with high Lp(a) and existing cardiovascular disease. Pelacarsen lowered Lp(a) by 77.7%, and events were the same on drug and placebo (12.3% vs 12.1%) over a median 4.7 years. Full results came out in NEJM on November 7, 2026.
The 2026 ACC/AHA guideline recommends measuring Lp(a) once in every adult (Class 1). It uses a high result to justify tighter LDL lowering and control of other risk factors. It never recommended a Lp(a)-lowering drug.
The trial tested one drug in people who already had disease and well-controlled LDL. It was also neutral in people starting at 90 mg/dL or higher. It does not show that a high Lp(a) is harmless, and it does not show that lowering Lp(a) can never help.
Check the unit on your report. Lp(a) is reported in nmol/L or mg/dL, and the two do not convert cleanly.

What Novartis announced. In a September 4 release, Novartis said the Lp(a)HORIZON phase III trial did not meet its primary endpoint: a composite of cardiovascular death, non-fatal heart attack, non-fatal stroke and urgent coronary revascularization requiring hospital admission. The trial enrolled 8,323 patients with elevated Lp(a) and established atherosclerotic cardiovascular disease. Lp(a) was lower on pelacarsen. BioPharma Dive put the reduction at about 80%. Those were company topline results. The full data followed in November.

The full results. Investigators presented the trial at the American Heart Association’s Scientific Sessions on November 7 and published it in the New England Journal of Medicine. Per TCTMD and Healio, Lp(a) fell from about 236 nmol/L at baseline to 64.4 nmol/L at 12 months (233.4 on placebo), a 77.7% reduction against placebo. The primary endpoint occurred in 12.3% on pelacarsen and 12.1% on placebo over a median 4.7 years (hazard ratio 1.02, 95% CI 0.90 to 1.15). In patients starting at 90 mg/dL (about 192 nmol/L) or higher, the hazard ratio was 1.00. The AHA release reports anaphylaxis in 19 patients on pelacarsen and none on placebo, and Healio puts discontinuation for adverse events at 20.6% against 7.5%. TCTMD reports that Novartis has discontinued pelacarsen’s development program for atherosclerotic disease.

Why the drug mattered to testing. The guideline describes Lp(a) levels as genetically driven. BioPharma Dive reports that physicians often skip the test because no drug exists to act on a result. A positive trial would have changed that. A negative one leaves the situation where it was in 2025.

What the trial cannot tell you. Every participant already had cardiovascular disease, and TCTMD reports mean LDL cholesterol around 66 mg/dL on standard treatment, so the background risk was well managed. It tested one drug, one mechanism, one population. In September, analysts quoted by BioPharma Dive wanted to know how baseline Lp(a) related to benefit and how close the result came to significance. The full data answer both: no benefit at any baseline level tested, and a hazard ratio of 1.02. Experts quoted by TCTMD offered possible reasons, all speculative: advanced disease, residual Lp(a) on treatment, side effects, and follow-up too short for a lifelong exposure. Senior author Steven Nissen said the result applies to pelacarsen only. Amgen’s olpasiran and Lilly’s lepodisiran are still in development. BioPharma Dive notes olpasiran’s deeper lowering (over 95%) could matter if depth drives benefit. I found no outcomes report from either.

What the guideline says. The 2026 ACC/AHA dyslipidemia guideline, published in May, gives a Class 1 recommendation to measure Lp(a) once in an adult’s lifetime. TCTMD summarizes it: an elevated level is an indication for more intensive LDL-cholesterol lowering and management of other risk factors, also Class 1. Neither recommendation names an Lp(a)-lowering drug, so the trial result removes nothing the guideline said. After the full results, guideline author Donald Lloyd-Jones told TCTMD that the trial does not change the Class 1 recommendation to measure Lp(a) at least once.

Reading your number. Healio’s guideline summary treats 125 nmol/L or higher as a risk enhancer, with roughly 1.4 times the cardiovascular risk, and 250 nmol/L or higher as more than double. TCTMD quotes the same threshold as 50 mg/dL. Do not convert between the two yourself. A 2023 survey of UK laboratories states that converting mass units to molar units introduces inaccuracy, and recommends nmol/L for reporting. Compare your result with the threshold in the unit printed on your report.

If your Lp(a) is high. The guideline’s answer is unchanged: push down what you can. That means LDL cholesterol (or ApoB, if you have it), blood pressure, glucose, and smoking, in a conversation with a clinician who has seen the number. If you have never had it measured, it usually has to be requested by name. Our lipid panel guide covers what a standard panel leaves out, and a separate post covers what cohort studies show about lifespan with a high Lp(a).

What to watch. With the full Lp(a)HORIZON data out, the open question is the other drugs. TCTMD lists OCEAN(a)-Outcomes and OCEAN(a)-PreEvent (olpasiran), ACCLAIM-Lp(a) (lepodisiran) and MOVE-Lp(a) (muvalaplin), and Nissen notes trials in primary prevention and aortic stenosis. If deeper lowering turns out to matter, the drug case reopens. If it does not, Lp(a) stays a risk marker you test once and manage around.

Updated November 9, 2026. This post ran on September 29 using Novartis’s topline announcement and said the full data were still to come. They were published on November 7. We added the full-results section, the event rates and the subgroup result, and replaced the lines that said the data were pending. The conclusion did not change.

Why this matters for you

Lp(a) is one of the lipid markers a routine panel skips. See how to read a lipid panel and what a high LDL result means, the marker the guideline tells you to tighten when Lp(a) is high.

Disclaimer
This is commentary on published research, not medical advice. Talk to your doctor before changing anything based on a study.
Free · No account · 45 seconds

See which lipid markers your report includes

Upload your blood report and see what was tested, what each marker means, and which three to deal with first.

Analyze My Blood Test →
Any lab PDF or phone photo · Processed in memory, never stored
FixFirst is free, with no ads and no account. If this post helped, a coffee keeps it that way.